PT - JOURNAL ARTICLE AU - Maier, Lisa AU - von Krüchten, Ricarda AU - Lorbeer, Roberto AU - Filler, Jule AU - Nattenmüller, Johanna AU - Thorand, Barbara AU - Koenig, Wolfgang AU - Rathmann, Wolfgang AU - Bamberg, Fabian AU - Schlett, Christopher L. AU - Peters, Annette AU - Rospleszcz, Susanne TI - Distribution and associated factors of hepatic iron – a population-based imaging study AID - 10.1101/2021.10.11.21264730 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.11.21264730 4099 - http://medrxiv.org/content/early/2021/10/14/2021.10.11.21264730.short 4100 - http://medrxiv.org/content/early/2021/10/14/2021.10.11.21264730.full AB - Context Hepatic iron overload can cause severe organ damage. Therefore, an early diagnosis is crucial, and identification of modifiable risk factors could help to prevent manifestations of iron-driven complications.Objective To investigate the sex-specific distribution of hepatic iron content (HIC) in a population-based sample, and to identify relevant associated factors from a panel of markers.Methods We analysed N=353 participants from a cross-sectional, population-based cohort in Southern Germany (KORA FF4) who underwent whole-body magnetic resonance imaging. HIC was assessed by single-voxel spectroscopy with a high-speed T2-corrected multi-echo technique. A large panel of markers, including anthropometric, genetic and laboratory values as well as behavioural risk factors were assessed. Relevant factors associated with HIC were identified by variable selection based on LASSO regression with bootstrap resampling.Results HIC in the study sample (mean age at examination was 56.0 years, 58.4% were men) was significantly lower in women (mean±SD: 39.2±4.1 s-1) than in men (41.8±4.7 s-1, p<0.001). Relevant factors associated with HIC were HbA1c and prediabetes for men, and visceral adipose tissue and age for women. Hepatic fat, alcohol consumption, and a genetic risk score for iron levels were associated with HIC in both sexes.Conclusion There are sex-specific associations of HIC with markers of body composition, glucose metabolism and alcohol consumption.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has been financed in part through HGF Future Topic AMPro. The KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC–Health), Ludwig–Maximilians–Universität, as part of LMUinnovativ. The KORA MRI sub–study received funding by the German Research Foundation (DFG, Deutsche Forschungsgemeinschaft, BA 4233/4–1, http://www.dfg.de), the Centre for Diabetes Research (DZD e.V., Neuherberg, Germany) and the German Centre for Cardiovascular Disease Research (Berlin, Germany, grants 81X2600209 and 81X2600214). The KORA–MRI sub–study was supported by an unrestricted research grant from Siemens Healthcare. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the Ludwig Maximilians University Munich approved this study. The Bavarian Chamber of Physicians approved this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRestrictions apply to the availability of some or all data generated or analysed during this study to preserve patient confidentiality or because they were used under license. The corresponding author will on request detail the restrictions and any conditions under which access to some data may be provided.